SA国际传媒

SA国际传媒

FDA gives clearance to plant-based hemostatic gel

TRAUMAGEL is designed for temporary external use for controlling moderate to severe bleeding

Cresilon-TRAUMAGEL-Hemostatic-Gel

Cresilon receives FDA 510(k) clearance for TRAUMAGEL

Cresilon

By Bill Carey
SA国际传媒

NEW YORK 鈥 , a biotechnology company focused on hemostatic medical device technologies, received U.S. Food and Drug Administration clearance for for the temporary external use for controlling moderate to severe bleeding.

Cresilon鈥檚 plant-based hemostatic gel technology is designed to stop and control life-threatening bleeding, according to a .

鈥淭he ability to rapidly stop bleeding at the point of care and halt a life-threatening hemorrhage can be the difference between life and death for people with traumatic wounds,鈥 Cresilon CEO and co-founder Joe Landolina said. 鈥淭he FDA clearance for TRAUMAGEL is a monumental milestone for Cresilon and brings us another step forward in our mission to save lives and transform the standard of care in wound treatment.鈥

TRAUMAGEL is Cresilon鈥檚 second FDA clearance for human use. The first was granted in 2023 for Cresilon Hemostatic Gel for minor cuts, lacerations and abrasions.

Trending
Thousands of first responders and survivors rely on the WTC Health Program to get treatment related to injuries and illnesses caused by the toxins at Ground Zero
The NIOSH layoffs impact nearly 200 employees, including mining safety and protective equipment programs as part of a broader federal workforce reduction under a Trump-era executive order
Farmington Hills police officers arrived to find fire showing from the house and reports of people trapped inside
An SUV crashed into a Manalapan home, causing a fire that destroyed part of the house